Autonomix Medical, Inc. (NASDAQ:AMIX) Short Interest Down 15.6% in February

Autonomix Medical, Inc. (NASDAQ:AMIX) saw a significant decrease in short interest in February. As of February 13th, there was short interest totaling 489,419 shares, a decrease of 15.6% from the January 29th total of 579,655 shares. Currently, 7.6% of the company’s shares are short sold. Based on an average trading volume of 233,238 shares, the days-to-cover ratio is currently 2.1 days. Based on an average trading volume of 233,238 shares, the days-to-cover ratio is currently 2.1 days. Currently, 7.6% of the company’s shares are short sold.

Autonomix Medical Price Performance

Shares of NASDAQ AMIX opened at $0.40 on Wednesday. Autonomix Medical has a 1 year low of $0.34 and a 1 year high of $2.82. The firm has a 50-day simple moving average of $0.45 and a two-hundred day simple moving average of $0.81. The company has a market cap of $2.73 million, a P/E ratio of -0.11 and a beta of -2.80.

Autonomix Medical (NASDAQ:AMIX) last issued its quarterly earnings results on Wednesday, February 11th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.10. As a group, equities research analysts expect that Autonomix Medical will post -10 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Autonomix Medical in a report on Wednesday, January 21st. Maxim Group dropped their price target on Autonomix Medical from $5.00 to $2.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Autonomix Medical currently has a consensus rating of “Hold” and an average target price of $2.00.

Autonomix Medical Company Profile

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.